Charles River Acquires Blue Stream Laboratories

Jun 27 2016

Charles River has acquired Blue Stream Laboratories, an analytical contract research organization (CRO) supporting the development of complex biologics and biosimilars. Blue Stream is recognized for its expertise in structural and functional protein characterization, comprehensive biosimilar comparability programs, formulation development of protein and peptide therapeutics, and the development and ICH validation of QC and characterization methods suitable for cGMP lot release and stability programs.

Acquiring Blue Stream Laboratories enhances our position as a leading CRO by increasing our ability to support biologic and biosimilar development from early cell line characterization through late-stage clinical testing and commercialization. Moving forward, we’ll be able to provide our clients with a complete solution as they continue to focus on the development of biologic and biosimilar entities.

Read the press release »

Learn more about our biologics testing capabilities »